Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Atragen

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Tretinointretinoin liposome

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2003
Highly Cited
2003
Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers.
PURPOSE To determine single-and multiple-dose pharmacokinetics of liposomal-all- trans -retinoic acid (Atragen) following… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
2000
2000
The Nonclinical Safety Evaluation of the Anticancer Drug Atragen® (Liposomal All-Trans-Retinoic Acid)
ATRAGEN® is a liposome-encapsulated intravenous (IV) formulation of the anticancer drug all-trans-retinoic acid (tretinoin… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
1999
1999
Assessment ofall-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia
All-trans retinoic acid (ATRA) is currently widely used in the therapy of acute promyelocytic leukimia and is being testedin… Expand
1998
1998
Differences in the Lipoprotein Distribution of Free and Liposome-Associated All-trans-Retinoic Acid in Human, Dog, and Rat Plasma Are Due to Variations in Lipoprotein Lipid and Protein Content
ABSTRACT The objective of the proposed study was to determine the distribution in plasma lipoprotein of free all-transretinoic… Expand
1997
1997
A MULTICENTER, PHASE II/III STUDY OF ATRAGEN™ (Tretinoin Liposomal) IN PATIENTS WITH AIDS-ASSOCIATED KAPOSI'S SARCOMA: 14
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE